Goldman Sachs Group (GS) 157.83 $GS Stock Market News

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Goldman Sachs Group (GS) 157.83 $GS

Stock Market News for August 04, 2016
Zacks Equity Research - Zacks Investment Research - 1 hr 8 mins ago
Gains in energy and financial shares helped major indexes end in the green on Wednesday
GS: 157.83 (-0.51), ADP: 88.52 (+0.33), JPM: 64.45 (-0.21), C: 43.95 (+0.06), XOM: 87.49 (unch), WMB: 25.09 (-0.58), HP: 62.42 (-0.61), BRK.B: 143.47 (-0.16), CVX: 100.32 (-0.29), SLB: 79.49 (-0.13), MS: 28.09 (-0.33)

Goldman Sachs (GS) to Pay $36.3 Million for Using Confidential Data
Zacks Premium Research - Zacks Investment Research - Wed Aug 03, 3:46PM CDT
The Federal Reserve is penalizing the bank after it used confidential information to gain more business from clients.
GS: 157.82 (-0.52)

Is Goldman Sachs Right on Crude?
Tracey Ryniec - Zacks Investment Research - Tue Aug 02, 4:59PM CDT
Sheraz Mian and Tracey Ryniec discuss where crude is headed for the second half of the year.
OIS: 30.70 (-0.09), GS: 157.82 (-0.52), HAL: 42.77 (-0.17), SLB: 79.49 (-0.13), URI: 76.63 (+0.03)

SmarTrend Watching for Potential Rebound in Shares of Goldman Sachs Group After 1.19% Loss
Comtex SmarTrend(R) - Tue Aug 02, 12:55PM CDT
Goldman Sachs Group (NYSE:GS) traded in a range yesterday that spanned from a low of $155.94 to a high of $158.46. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.93 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GS: 157.82 (-0.52)

After Yesterday's Decline of 1.19%, Goldman Sachs Group Offers Investors Better Value
Comtex SmarTrend(R) - Tue Aug 02, 12:53PM CDT
Goldman Sachs Group (NYSE:GS) traded in a range yesterday that spanned from a low of $155.94 to a high of $158.46. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.93 on volume of 1.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GS: 157.82 (-0.52)

5 Reassuring Dividend Stocks to Beat August Scare
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:38AM CDT
Stocks losing momentum, possibility of market turbulence and no imminent rate hike all scream for investing in dividend stocks.
GS: 157.82 (-0.52), QCOM: 61.02 (+0.01), BPL: 70.78 (-0.46), OHI: 35.81 (+0.39), PFG: 45.82 (-0.01), M: 33.42 (-0.01), DB: 12.68 (-0.01)

5 Best Top Ranked Stocks of July
Swarup Gupta - Zacks Investment Research - Mon Aug 01, 10:49AM CDT
Markets enjoyed a month of strong gains on the back of a modest increase in earnings numbers and impressive economic data.
AMZN: 762.24 (+7.60), F: 12.10 (-0.03), OMN: 9.08 (+0.03), BLK: 367.59 (-0.57), STX: 31.03 (+0.30), C: 43.94 (+0.05), MXL: 21.53 (+0.09), AKS: 6.07 (-0.15), WFC: 47.81 (+0.24), BAC: 14.40 (-0.08), MS: 28.09 (-0.33), GS: 157.82 (-0.52), JPM: 64.43 (-0.23), TPX: 76.02 (-0.35), PNC: 84.19 (+0.34), MSFT: 57.13 (+0.16), AAPL: 105.83 (+0.04)

Research Reports for Facebook, DuPont, Gilead & Others
Sheraz Mian - Zacks Investment Research - Thu Jul 28, 1:23PM CDT
Research Reports for Facebook, DuPont, Gilead & Others
GS: 157.82 (-0.52), GILD: 80.22 (+0.13), FB: 124.17 (+1.66), BCE: 47.63 (+0.37), ADI: 63.23 (+0.36), DD: 68.91 (unch), M: 33.42 (-0.01)

Bear of the Day: Interactive Brokers Group (IBKR)
Brian Hamilton - ZACKS - Mon Jul 25, 6:01AM CDT
Bear of the Day: Interactive Brokers Group (IBKR)
GS: 157.82 (-0.52), IBKR: 34.68 (-0.14), MS: 28.09 (-0.33)

Goldman Sachs Group (GS) Breaks Through Support at $162.20
Comtex SmarTrend(R) - Tue Jul 19, 8:37AM CDT
Shares of Goldman Sachs Group (NYSE:GS) opened today below their pivot of $163.14 and have already reached the first level of support at $162.20. Investors may be interested in a cross of the next downside pivot targets of $161.06 and $158.98.
GS: 157.82 (-0.52)

Goldman Sachs (GS) Q2 Earnings Beat; Costs Falls
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 8:14AM CDT
Goldman came out with earnings per share of $3.72, significantly beating the Zacks Consensus Estimate of $3.01. Lower expenses were primarily responsible for the beat.
GS: 157.82 (-0.52)

Market Rally Takes Breather Despite Q2 Earnings, June Housing Starts
Mark Vickery - ZACKS - Tue Jul 19, 3:52AM CDT
Not even June Housing Starts have been able to turn around futures this morning, after posting 4.8% in gains, compared with 1.7% in May.
NFLX: 92.54 (-0.56), GS: 157.82 (-0.52), IBM: 160.72 (+0.05)

How to Trade Goldman Sachs (GS) Ahead of Earnings
David Bartosiak - Zacks Investment Research - Mon Jul 18, 5:09PM CDT
David Bartosiak gave us his thoughts on Goldman Sachs before they report earnings tomorrow.
GS: 157.82 (-0.52)

Earnings Preview: Morgan Stanley (MS) vs. Goldman Sachs (GS)
Eric Dutram - Zacks Investment Research - Mon Jul 18, 4:39PM CDT
The broker dealer segment has been beaten down thanks to a weak trading environment and a sluggish outlook on the interest rate front. MS and GS look to set the record straight this week when they give their reports, but which is the best positioned for gains?
GS: 157.82 (-0.52), IAI: 39.21 (-0.02), MS: 28.09 (-0.33)

This Investment Bank Looks Like a Short Ahead of Earnings
ESTMZ - Mon Jul 18, 3:01PM CDT
The Goldman Sachs Group ( GS ) Financials - Capital Markets| Reports July 19, Before Market Opens Key Takeaways The Estimize community is looking for earnings per share of $3.10 on $7.62 billion in revenue, a 34% decline on the bottom and 14%...
SPY: 216.48 (+0.30), GS: 157.82 (-0.52), MS: 28.09 (-0.33)

SmarTrend Watching for Potential Pullback in Shares of Goldman Sachs Group After 1.19% Gain
Comtex SmarTrend(R) - Mon Jul 18, 11:57AM CDT
Goldman Sachs Group (NYSE:GS) traded in a range yesterday that spanned from a low of $162.01 to a high of $164.09. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $163.24 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GS: 157.82 (-0.52)

Dow 30 Stock Roundup: JPM Q2 Impresses, Orders for Boeing & United Technologies
Swarup Gupta - Zacks Investment Research - Mon Jul 18, 10:51AM CDT
The Dow notched up heavy gains during an eventful week, boosted by multiple factors.
MMM: 178.45 (+0.07), AA: 10.34 (-0.07), GE: 31.17 (+0.04), GS: 157.82 (-0.52), JPM: 64.43 (-0.23), UTX: 106.76 (+0.47), PFE: 35.29 (unch), XOM: 87.49 (unch), DD: 68.91 (unch), CVX: 100.32 (-0.29), BA: 131.69 (-0.18), VZ: 53.99 (+0.09)

Investment Management Earnings Preview: GS, IBKR, AMTD
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:36AM CDT
Investment management (part of the broader Finance sector) performed decently over the last several quarters. Volatility in the second quarter was heightened by Brexit related uncertainty which became more pronounced from the beginning of June.
GS: 157.82 (-0.52), IBKR: 34.68 (-0.14), AMTD: 30.07 (+0.03)

4 Blue Chips to Dazzle with Dow Nearly at 20,000
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 9:22AM CDT
With the Dow all set to hit the 20K mark, investing in solid blue-chip stocks should be a prudent move.
JNJ: 124.13 (+0.23), GE: 31.17 (+0.04), HD: 136.06 (-1.00), GS: 157.82 (-0.52), JPM: 64.43 (-0.23), IBM: 160.72 (+0.05), UNH: 143.39 (+0.51), MCD: 117.93 (+0.41), WMT: 72.91 (-0.03), INTC: 34.48 (+0.23), BA: 131.69 (-0.18), AAPL: 105.83 (+0.04)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading